Highest-materiality recent filing
Olaplex completes acquisition by Henkel subsidiary for $2.06/share, ~$1.4B equity value
Merger closed July 7, 2026; shareholders receive $2.06 per share in cash.
Olaplex Q1 net sales up 2.5% to $99.4M but swings to net loss of $5.3M; adjusted EBITDA falls 26.1%
Net sales up 2.5% to $99.4M; Specialty Retail -13.3% to $33.4M, Professional +12.3% to $38.8M, DTC +13.8% to $27.2M.
Olaplex to be acquired by Henkel for $2.06 per share ($1.4B equity value)
Cash consideration of $2.06/share represents ~55% premium over 3/25/26 close and ~45% premium over 30-day VWAP.
Olaplex Q4 sales up 4.3% to $105.1M; net loss widens to $13.1M from $8.8M
Q4 net loss of $13.1M ($0.02 diluted EPS loss) vs $8.8M loss ($0.01 loss) a year ago.
Olaplex Q3 net sales fall 3.8%, net income down 24.8%; reaffirms guidance
Net sales $114.6M, down 3.8% YoY; US sales -14.6%, international +7.1%.
Olaplex Q2 net loss $7.7M vs prior-year income; revenue up 2.3% to $106.3M
Net loss of $7.7M (diluted EPS -$0.01) vs net income of $5.8M ($0.01) in Q2 2024.
Olaplex Q1 net sales down 1.9% to $97M; net income drops to $0.5M
Net sales $97.0M (-1.9% YoY); diluted EPS $0.00 vs $0.01.
Olaplex Q4 net sales $100.7M (-9.8%), net loss; Professional channel down 27% YoY
Q4 net sales $100.7M, down 9.8% YoY; net loss $8.8M vs net income $14.1M a year ago.
Olaplex Q3 net sales down 3.6% to $119.1M, EPS $0.02; cuts FY2024 outlook
Net sales $119.1M, down 3.6% YoY; Professional channel fell 12.6%, DTC rose 6.8%.
Olaplex Q2 revenue down 4.8% to $103.9M; reiterates FY2024 guidance
Net sales $103.9M, down 4.8% YoY; diluted EPS flat at $0.01, adjusted EPS flat at $0.03.
Olaplex appoints Catherine Dunleavy as COO and CFO effective August 13, 2024
Catherine Dunleavy, 55, appointed COO and CFO effective Aug 13, 2024, succeeding interim CFO Paul Kosturos.
Olaplex appoints Paul Kosturos as interim CFO after Eric Tiziani resigns
Paul Kosturos appointed interim CFO effective May 6, 2024; succeeds Eric Tiziani who resigned same day.
Olaplex Q1 net sales fall 13.1% to $98.9M; diluted EPS $0.01
Net sales $98.9M (-13.1% YoY); professional channel down 19.9% to $38.7M, DTC down 15.7%, specialty retail -1.2%.
Olaplex CFO Tiziani resigns; Q1 net sales guidance reaffirmed at $92-97M
CFO Eric Tiziani resigns effective May 6, 2024; external search for successor launched.
Olaplex Q4 net sales down 14.5% to $111.7M; FY net sales down 34.9% to $458.3M
Q4 2023 net sales $111.7M vs $130.7M YoY (-14.5%); U.S. sales declined 27.9%, international down 0.7%.
Olaplex appoints Amanda Baldwin as CEO; sign-on bonus raised to $950k
Amanda Baldwin, 45, appointed CEO effective Dec 11, 2023, succeeding interim CEO John Bilbrey.
Q3 net sales down 30% YoY to $123.6M; adjusted diluted EPS $0.05 vs $0.11
Net sales of $123.6M, down 30.0% YoY; Specialty Retail fell 41.8%, Professional -23.3%, DTC -18.2%.
Olaplex names John Bilbrey interim CEO; Amanda Baldwin to succeed in Q4 2023/Q1 2024
JuE Wong steps down as President and CEO effective Oct 12, 2023; remains employed until Oct 20.
Olaplex Q2 net sales down 48% to $109M; revises FY2023 guidance lower
Net sales $109.2M (-48.2% YoY); net income $6.2M vs $87.7M; diluted EPS $0.01 vs $0.13.
Olaplex Q1 net sales $113.8M, down 38.9%; diluted EPS $0.03 vs $0.09
Net sales fell 38.9% to $113.8M; net income down 66.2% to $21.0M.
Olaplex Q4 net sales down 21.5% to $130.7M; net income falls 51.5%
Q4 net sales $130.7M vs $166.5M YoY; US sales down 28.0%, international down 13.4%.
Olaplex Q3 revenue up 9.2% to $176.5M; adjusted EPS flat at $0.11
Net income rose 7.4% to $60.8M; adjusted net income fell 1.6% to $73.3M.
Olaplex cuts FY2022 guidance, COO Tiffany Walden resigns effective Oct 18
Preliminary Q3 net sales ~$176.5M (+9.2% YoY); net income $59-61M; adjusted EBITDA $100-102M.
Olaplex Q2 2022 net sales up 38.6% to $210.9M; net income +77.7%; reaffirms FY22 guidance
Net sales $210.9M (+38.6% YoY); US sales +41.3%, international +35.2%.
Olaplex Q1 net sales up 57.6% to $186.2M; diluted EPS $0.09, adjusted $0.13
Net sales $186.2M (+57.6% YoY); diluted EPS $0.09, adjusted diluted EPS $0.13.
OLAPLEX FY21 net sales +112% to $598.4M; EPS $0.32, adj. EPS $0.40; Q4 sales +79%
FY 2021 net sales $598.4M (+112% YoY); net income up 462%.
New $675M term loan and $150M revolver replace prior $769M credit facility, using cash on hand to reduce outstanding debt.
Olaplex Q3 net sales up 81% to $161.6M; net income $56.6M; introduces FY2021 outlook
Net sales $161.6M (+81% YoY); gross margin improved 870 bps to 78.9%.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
In connection with the Merger, effective as of the Effective Time, John P. Bilbrey, Amanda Baldwin, Christine Dagousset, Pamela Edwards, Deirdre Findlay, Tricia Glynn, Jerome Griffith, Martha Morfitt, David Mussafer, Emily White and Michael White ceased to be members of the Company’s board of directors or any committee thereof.
In connection with the Merger, effective as of the Effective Time, Amanda Baldwin, John Duffy, Melisa Gill, and Martijn de Regt were appointed as directors of the Company.
Max materiality 1.00 · Median 0.65 · Most common event earnings